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ABsTrACT
Alpha-1 antitrypsin deficiency (AATD) is a cause of 
bronchiectasis. Guidelines for bronchiectasis from the 
British Thoracic Society do not recommend to routinely 
test patients for AATD. In contrast, guidelines for AATD 
recommend routine screening. This contradiction, in 
part, results from the lack of data from large studies 
performing comprehensive screening. We screened 1600 
patients with bronchiectasis at two centres in the UK 
from 2012 to 2016. In total, only eight individuals with 
AATD were identified representing 0.5% of the overall 
population. We conclude that routine screening for AATD 
in bronchiectasis in the UK has a low rate of detection. 
Further studies are required in different geographical 
regions, which may have a higher prevalence of AATD.
Bronchiectasis is a heterogeneous airway disease 
characterised by chronic respiratory symptoms and 
permanent dilatation of bronchi. Guidelines from 
the European and British Thoracic Societies recom-
mend systematic investigations for underlying 
causes, since there is specific treatment for some 
diseases that could have clinical and prognostic 
impact.1 2
Alpha-1 antitrypsin deficiency (AATD) is a 
potential cause of bronchiectasis and augmentation 
therapy is licensed in several countries, particu-
larly in cases of severe disease with airway obstruc-
tion.3 Prevalence of PiSZ and PiZZ phenotypes, 
the two most common phenotypes associated with 
lower serum alpha-1 antitrypsin (A1AT) levels and 
increased risk of lung disease, has been estimated to 
be 1:900 and 1:15.388, respectively, in the overall 
population in Scotland with a higher prevalence of 
1:4440 reported in England.4
The clinical utility of AATD screening in bron-
chiectasis patients remains unclear. The British 
Thoracic Society guidelines currently recommend 
against screening for AATD- based primarily on the 
results of Pasteur et al5 who screened 150 patients 
with bronchiectasis and found a frequency of AATD 
which was not different to the general UK popula-
tion. No patients with SZ or ZZ phenotype were 
identified in this study.5 A retrospective study of 202 
patients with bronchiectasis from France (1991–
1996) found a distribution of alpha-1 phenotypes 
that was not different to the distribution expected 
in the general population.6 In contrast, bronchiec-
tasis has been reported frequently in patients with 
known AATD.7 For example Parr et al studied 74 
patients with PiZZ genotype and found that 95% 
had bronchiectasis affecting a mean of 3.7 lobes. 
27% had bronchiectasis affecting more than four 
lobes and daily sputum production.7 Based on data 
such as this, guidelines for AATD suggest screening 
all patients with bronchiectasis for AATD.8 This 
contradiction, where bronchiectasis guidelines 
recommend against screening while AATD guide-
lines recommend routine testing, results in part 
from the lack of any large prospective studies eval-
uating the results of routine prospective screening.
We, therefore, investigated if routine measure-
ment of serum A1AT in the aetiological assessment 
of bronchiectasis was clinically useful in two large 
populations of UK adults.
New patients attending the Bronchiectasis Clinics 
at Ninewells Hospital and the Royal Brompton 
Hospital, London (RBH) for initial investigation 
of bronchiectasis aetiology were included in the 
study. All patients had documented bronchiectasis 
by high- resolution CT (HRCT) scans. Standard-
ised testing for aetiologies of bronchiectasis was 
performed including A1AT testing, but also testing 
for allergic bronchopulmonary aspergillosis (ABPA), 
immunoglobulins, functional antibodies and serum 
electrophoresis. Serum A1AT level was measured 
according to the local laboratory standard proce-
dures and in cases where the serum level was low, 
phenotyping was performed. At the Ninewells labo-
ratory, the level for phenotyping was 1.0 g/L and at 
RBH it was 1.3 g/L.
Between January 2012 and December 2016, 675 
people with bronchiectasis were investigated at 
Ninewells Hospital and 925 patients were investi-
gated at RBH. Characteristics of patients at both 
centres have been previously reported and are 
predominantly elderly females (median 67 years, 
60% female).
At the Scottish centre, we identified 17 patients 
(2.52%) with A1AT levels <1 g/L who went on 
to have phenotyping performed. In those with 
an abnormal A1AT level, the mean was 0.79 g/L 
(+/−0.18). Phenotypes were PiMZ in 13 patients 
(average 0.86 g/L+/-0.09), PiSZ in three patients 
(average 0.7 g/L+/-0.06) and PiZZ in one patient 
(0.20 g/L. We, therefore, identified one patient with 
severe AATD disease (PiZZ) from 675 screened and 
three patients with moderate AATD disease (PiSZ). 
The minimum protective level of A1AT has been 
reported as 0.8 g/L. On this basis we identified six 
individuals with deficient A1AT levels.
From the 925 patients screened at RBH 254 
patients had phenotyping performed due to a level 
<1.3 g/L of which 21 had levels <1 g/L equating 
to the Ninewells cut- off. From phenotyping we 
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Figure 1 Frequency of different alpha-1 antitrypsin deficiency 
phenotypes in the two cohorts. Predicted values are the % of 
subjects expected to be identified in the general population based on 
reported population frequencies of PiZZ alpha-1 antitrypsin deficiency 
(unweighted prevalence estimates).3 4 RBH, Royal Brompton Hospital.
identified seven patients with PiZZ with an average level 
of 0.23 g/L (0.05), three patients with PiSZ or PiS where the 
second allele could not be identified with an average of 0.93 
(0.23). Twenty- eight patients were identified with PiMZ with an 
average of 1.01 g/L (0.16). Eight patients had A1AT levels below 
the protective threshold of 0.8 g/L. Results are summarised in 
figure 1.
Augmentation therapy is recommended only to non- smoking 
patients with pulmonary emphysema and reduced or progres-
sive decline on lung function.3 Non- smoking PiMZ individuals 
are not known to have increased risk of lung disease9 and PiSZ 
phenotype is not usually an indication for augmentation therapy, 
therefore, in 675 bronchiectasis patients, only one (0.15%) 
patients in Scotland and 7 (0.8%) in England had severe AATD 
that could possibly benefit from augmentation therapy. The 
slightly higher prevalence in England may reflect true differences 
as the reported prevalence is higher in England, or differences in 
the characteristics of patients referred to each centre.
In the UK, National Health System, A1AT serum assay and 
phenotyping costs were £2.45 and £35.50, respectively, which 
means that the total cost of screening in this project was 
£2257.25 to identify a single individual eligible for treatment 
in the Scottish site and £11 283.25 to identify seven patients 
eligible for treatment in the English site. The higher costs at the 
English site reflect a higher number of patients included and the 
lower threshold for phenotyping of 1.3 g/L.
Augmentation therapy have been shown to reduce, but not 
eliminate, emphysema progression3 and to reduce the frequency 
of hospital admissions for acute exacerbations of chronic obstruc-
tive pulmonary disease.10 However, to our knowledge, there 
have been no studies evaluating clinical benefits for bronchiec-
tasis patients with AATD. It is important to note that augmen-
tation therapy, despite its clinical benefits in selected patients, is 
not available in some countries, including the UK.
Early diagnosis of AATD is important for much more than 
augmentation therapy, as these patients also benefit from smoking 
cessation programmes and genetic counselling. Awareness that 
patients have impaired protease- anti- protease balance may lead 
to closer monitoring and a lower threshold to treat chronic 
infection. However, our findings show that the prevalence of 
AATD in bronchiectasis patients is relatively low compared with 
other reported aetiologies which are routinely screened for such 
as ABPA, and that implementation of routine screening of these 
patients does not significantly impact on clinical management. 
Our results are derived from two UK centres and a predomi-
nantly Caucasian population. It is possible that a higher rate 
of detection of AATD would be found in other geographical 
regions in the UK, or in other countries. The study has limita-
tions including that we screened two unselected bronchiectasis 
populations and did not collect detailed phenotypic data. We 
cannot, therefore, comment on whether more focused screening, 
for example, by limiting testing to those with airflow obstruc-
tion or CT detected emphysema, would have a great pickup 
rate. This will require further studies. A multicentre European 
cohort study that incorporates standardised testing for AATD is 
currently enrolling (NCT03791086) and will provide broader 
prevalence estimates as well as more detailed phenotypic data.
In summary, screening of an unselected UK bronchiectasis 
population for AATD identifies severe AATD in less than 1% 
of cases.
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